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“If you can’t see a dilemma in this situation you should probably regard it as a 
warning”. A metasynthesis and theoretical modeling of general practitioners’ opioid 
prescription experiences in primary care. 
Kennedy, M.; Pallotti, P.; Dickinson, R.; Harley, C. 
Introduction 
Worldwide prevalence of prescription opioid use has tripled since 1991, the greatest 
increases occurring in the USA and Canada. 1-3 Recent UK studies have highlighted an 
increase in the prescribing of opioids in primary care, most prominent in areas of social 
deprivation.4-7 These patterns have emerged despite lack of evidence of efficacy of opioids 
when used in the long-term but clear evidence of dose-dependent harmful outcomes for 
patients.8  
Prescribing medication, regardless of the condition being managed, is a complex process 
as it requires the GP to consolidate evidence based recommendations with the patient’s 
presenting complaint and co-morbidities to recommend a course of action having reached a 
consensus with the patient.9 GP-patient encounters centred on the prescribing of opioids are 
particularly complex given the potential for adverse outcomes from these medications and 
the understandable concern about potentially inappropriate use and addiction. However, 
being overly-cautious can result in the under-prescribing of analgesics particularly in 
medically complicated patients. This can lead to uncontrolled pain with a negative impact on 
quality of life.10 
Several qualitative studies have indicated that the prescribing of opioids for chronic non-
malignant pain (CNMP) in primary care is influenced by the resources available to the GP in 
addition to knowledge, experience and beliefs of the prescriber. For instance, ease of access 
to physiotherapy or pain specialists, perceived or actual risk of opioid related side-effects, 
concerns about misuse of opioids and professional experience in the management of CNMP 
are factors that alone or in combination influence the prescribing decision-making process. 
11-13 These issues may be further compounded by a sense of scrutiny from professional 
authorities which may further influence the GPs approach to opioid prescribing. 14 
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As most opioids prescriptions are initiated by a patient’s GP, it is essential that we 
understand the dynamics of a GP-patient consultation which leads to the prescribing 
decision. 7 The aim of this study is to identify and synthesize the qualitative literature on the 
factors influencing the nature and extent of opioid prescribing in CNMP by GPs in primary 
care. The secondary aim is to develop a theoretical model that describes the relationship 
between factors influencing prescribing of opioids for CNMP by GPs. 
Method 
A systematic search was conducted to identify eligible studies followed by a thematic 
synthesis of the included studies. Thematic synthesis involves the analysis of primary 
qualitative literature and provides a framework to integrate findings.15 This is reported 
using the ‘Enhancing transparency in reporting the synthesis of qualitative research: the 
ENTREQ statement’, a 21 item checklist.16 The systematic review was registered with the 
International Prospective Register of Systematic Reviews (PROSPERO), registration number 
CRD42017060017. Ethics approval was not required as the study did not involve human 
subjects. The completed ENTREQ and PRISMA statements are provided in Appendix 1 and 2 
respectively.  
Search Strategy 
A search strategy was devised to identify all available studies on the topic of GPs prescribing 
opioids for CNMP. The inclusion criteria for this review were that studies: a) document GP’s 
experiences and behaviours relating to prescribing opioids for CNMP in a primary care 
setting; b) were published in peer-reviewed journals and indexed in key clinical and 
scientific databases; and c) used a qualitative or mixed-method methodology. Studies were 
excluded from the review if they were non-English language, theoretical or methodological 
articles, policy documents, conference abstracts or presentations.  
The searches were conducted across the following databases including MEDLINE, 
Embase, PsychINFO, Cochrane Database, International Pharmaceutical Abstracts, Database 
of Abstracts of Reviews of Effects, CINAHL and Web of Science. These databases were 
systematically searched from 1986, the year of the development of the WHO analgesic ladder 
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to January 2017, the search was repeated to identify any relevant papers published from 
January 2017 - February 2018. The search strategy is provided in Appendix 3. Search 
descriptors included chronic pain, opioid, attitude and general practice. Reference lists of 
included articles were searched however handsearching was not conducted. The PRISMA 
flowchart summarises the search, review and selection process (Figure 1). 
Records identified through database 
searching 
(n = 7020) 
Records after duplicates removed 
(n = 4085 ) 
Records screened 
(n = 4085) 
Records excluded 
(n = 4064) 
Full-text articles assessed 
for eligibility  
(n = 21) 
Full-text articles excluded: 
(n = 8) 
Insufficient qualitative data (n=4) 
Focus on specific disease state (n=1) 
Not specifically GPs- included other 
primary care prescribers (n=3) Studies included in 
quantitative synthesis 
(meta-synthesis)  
(n = 13) 
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Figure 1: Search strategy 
Study Selection 
Two reviewers (REMOVED FOR ANONYMITY) independently screened titles and abstracts 
of all identified records to determine eligibility for inclusion in the review. Inconsistencies in 
selection were examined following review of titles and abstracts. The reviewers then 
independently assessed the full text of the articles. Disagreements were resolved by a third 
member (REMOVED FOR ANONYMITY) of the research team. 
Quality Assessment 
The quality of the studies was assessed using the Critical Appraisal Skills Programme (CASP) 
tool for qualitative research. 17 The CASP checklist highlights the information that should be 
included in a qualitative report and is widely used in qualitative reviews. 18 Two reviewers 
(REMOVED FOR ANONYMITY) assessed the quality of each study and a decision on the 
inclusion of studies was made with agreement of all authors.  
Data synthesis and analysis 
The results were organised using the process of Thematic Network Analysis (TNA). 19 TNA 
is a way of coding, organising and identifying emergent themes in a systematic way. All text 
in the included papers that were results or findings from the study were coded for basic 
themes by two researchers (MCK & PP) independently. Initial basic themes described the 
subject of the data extracted and did not attempt to interpret the data 20. All data extracted 
from each paper was indexed and an overarching coding framework developed. All coded 
papers were then reviewed by two researchers (REMOVED FOR ANONYMITY) and where 
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necessary re-coded. For example, some codes were merged and some were broken down 
into two or more codes as further data nuanced the emergent themes. A final check was 
completed to ensure codes were used consistently and exhaustively for all texts. Codes were 
then collated and each code was analysed to "identify the underlying patterns and 
structures" 19. Memo’s and journal entries written during the coding were included at this 
stage to examine the semantic features of each code; organising themes were developed 
through this process. The organising themes were then discussed by the two main 
researchers again (MCK & PP) and grouped into the global themes of the research. Data 
analysis was conducted using NVIVO Version 11 software. 
Results 
The search identified 7020 titles. Excluding duplicates (n=2935), 4085 titles were screened; 
21 full text articles were reviewed. Thirteen articles were included in the review, the 
characteristics of these studies and associated CASP scores are presented in Table 1. Nine 
were from the USA, 3 from the UK and 1 from Sweden. The basic codes underpinning the 
organising themes are presented in Table 2. Figure 2 provides an overview of the organising 
and global themes. Some basic codes were incorporated into more than one organising 
theme. Some organising themes are included in more than one global theme. This 
intersection of themes is normal and is demonstrative of both the close agreement of the 
papers as to the major issues and the complex nature of GP-patient relationships and 
encounters thus described.  
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Figure 2: Organising and global themes 
Suspicion Axis 
This global theme describes the patient, GP and context variables which raise or lower a GP’s 
suspicion of addiction and dependency, substance abuse, criminal activity, health system 
‘gaming’ or other misuse of controlled prescription drugs. Factors such as the long-standing 
relationship and continuity of care between a GP and patient, demographic patient factors 
and the presence or absence of a definite diagnosis or aetiology of pain all mediate the 
variables in this axis of decision making.  
Trust and mistrust 
This theme appeared frequently across papers and is about the work the GP and the patient 
must do to gain and keep trust in each other. Characteristics, such as expectations of patient’s 
behavior based on stereotypes, play a part, but so too does the history between the patient 
and GP. Trust is a processual factor in this context, it is built over time but can be eroded 
quickly if a GP feels that the patient is trying to manipulate them. The attempt by a patient to 
obtain opioids is often automatically a suspicious act in the eyes of the GP. However, a patient 
in pain seeking relief in this respect will not necessarily present differently from one seeking 
opioids for addiction or dependence. 
•Trust and mistrust
• Importance of aetiology
•Monitoring
Suspicion Axis
•Physical and psychological harm
•The morality of addiction
•Monitoring
Risk Axis
•Consult variablesDisagreement Axis
• Inadequate pain management
•Systems
•Monitoring
System Level 
Factors
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‘I think everybody’s fingers get burnt with people who you give the opioids to with a more 
trusting attitude than maybe you should have and the problem has quickly come back to you 
with needing more and more opioids.” 21 
GPs also doubted the patients’ trust in both themselves and the risk-benefit analysis they 
made about opioid use. Further, the GPs noted that the stigma of opioids, especially in some 
communities, and that sometimes put patients off using them even when the GP’s decision 
was that they would be helpful. 
“Patients hear the word codeine or some [other opioid] that they recognize and they think of it 
as a street drug, and don’t want to be associated with that. I think in this population, when 
street crime is so rampant, and they have families who have been hurt by street crime or family 
members who are in jail because of selling, patients are very hesitant.” 22 
The demographic factors of a patient often changed the doctor’s suspicion that a patient 
might be abusing and/or selling prescription drugs. Generally, GPs reported that they were 
likely to have less suspicion of misuse in older patients and sometimes racial and socio-
economic factors also influenced them.  
“I think if someone’s history shows that they have an addictive personality, whether it be street 
drugs, alcohol, smoking pot, whatever that theoretical concern is, but the patients I’ve used 
opiates for in non-cancer are nearly always the elderly with joint pain and I don’t have any 
concerns about them, no.” 21 
However, many GPs were very aware of this tendency towards demographic stereotyping 
and actively reflected on this to avoid prejudice in their care giving, although their 
assumption was usually towards the negative view that anyone would abuse prescription 
medication. 
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“That there’s a disconnect, saying, my brain wants to say…what we teach the residents… [that] 
anybody on narcotics [should have an Opioid Treatment Agreement], even if it’s the sweetest 
little 85-year-old woman who looks like your grandmother, versus, you know, some guy from 
the ghetto wearing his pants down at his knees… it shouldn’t really matter.”  23 
Importance of aetiology 
The recognition of the difficulties inherent in subjective pain assessment is at the heart of 
the GP decision making process. A diagnosed etiology helped a GP to feel more confident in 
the patient’s reports of pain, but even then, the extent of the pain was hard to gauge. 
“Pain is so subjective and so that’s where the difﬁculty lies . . . I ﬁnd it hard to say how someone’s 
pain can be judged by someone else.” 24 
The importance of an aetiology of the patient’s pain was a critical factor in the GP’s level of 
suspicion of abuse or aberrant prescription use. For patients who did not have an easily 
identifiable pathology, this led to difficulties for the GPs in managing their reported pain. 
“I feel this as a physician, when I see a patient who has, you know, a pathological fracture on 
an X-ray... if there’s something objectively definable it does change the way that I approach the 
patient.” 25 
Risk Axis 
GPs conduct a risk-benefit analysis when deciding to initiate or continue a prescription for 
opioids. Three crucial elements in this decision making are the harm to the patient, the harm 
to society and the harm to the GP themselves in terms of feelings of guilt and even the fear of 
professional sanctions should an incident occur. 
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Physical and psychological harm 
Many of the GPs explicitly discussed the fact that they would prioritise risk avoidance over 
adequate pain relief. This is demonstrative of the ‘devil and deep blue sea’ conundrum that 
GPs face: the potentially devastating effects of addiction mean that adequate management of 
pain, a key professional obligation, is not always possible. 
“For chronic pain in someone with a non-terminal type of illness you’ve got to weigh up what 
you are giving them in the long term, what are the potential side effects, is there an issue with 
addiction and you’re not going to just be increasing … For chronic pain, non-malignant pain, I 
think there has to be an acceptance that you are not necessarily going to get them pain free 
because they’ve got the rest of their lives to live as well ...” 21 
Related to the fear of causing harm was the guilt some GPs experienced, or might experience, 
due to opioid-related adverse events, causing them to think carefully before issuing a 
prescription: 
“If something does happen to them, you feel guilty and want to crawl under a table when they’re 
in the emergency room and you get the call that they fell while on the fentanyl patch you gave 
them. That kind of experience is powerful and definitely factors into the equation.” 22 
Many GPs worried about the effect of frailty in their elderly patients, because of the much 
higher risks of side-effects or accidental injury. However, they also worried less about 
addiction in much older patients so the risk axis is complex to negotiate for frail patients. 
“I just have a hard time prescribing opioids in my older patients. I get frightened with 80+ year 
olds; how are they going to respond? Am I going to absolutely drop them to the floor even with 
a small dose?” 22 
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Patients with physical and mental illnesses in addition to their chronic pain were seen as 
particularly hard to prescribe for because of the difficulties in predicting their likely 
response to opioids and also their risk of becoming addicted. Some GPs saw addiction as a 
psychiatric co-morbidity in and of itself, and the resultant confusion about how to both 
manage pain with addictive substances and treat the addiction itself were very apparent.  
Morality of addiction 
The nature of the drug itself, its addictive qualities but also its situation in the moral and legal 
ambiguity as a controlled substance given for a more or less valid reason, changed the nature 
of the GP-patient relationship. GPs view themselves as gatekeepers, charged with 
determining the appropriateness of an opioid prescription for their patient. However, this is 
not merely informed by an objective clinical assessment but consideration of personal 
motivations in the context of current or previous psychosocial concerns. Implicit in the 
prescribing decision is a moral judgement.  
 “In most doctor–patient relationships we learn to listen to the patient and accept their 
testimony ... in some instances [in opioid prescription consults], to be quite honest, we are 
interviewing the patient as if we are a police officer or a lawyer and we’re trying to find flaws 
in their story ... So, there is a different relationship here.” 25 
Disagreement Axis 
This global theme concerns the level of agreement between patient and physician about the 
prescribing outcome from the consultation. Whether the patient is given opioids or not is not 
relevant to this axis, it is more concerned with the patient and GPs’ mutual acceptance or 
conflict about the final management plan. Factors such as previous relationship with the 
patient as well as the factors discussed above in the suspicion axis, influence the likelihood 
of GP-patient agreement but it is worth noting that the necessity to preserve trust itself did 
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often lead GPs to make prescriptions that they were otherwise concerned about. Trust in a 
GP-patient relationship is crucial to any effective management plan, but all the GPs who 
discussed it hinted that it was easily disrupted. Again, this also links back to the importance 
of an identified aetiology, which at least gave the GP confidence that a prescription was 
necessary. 
‘‘I don’t know what the pain is like. They really might be in pain. I don’t want to challenge them 
and have them think that I don’t trust them. I don’t want to make them any more miserable.’’ 26 
It is perceived as difficult for a GP to distinguish between drug seeking behaviour and pain 
relief seeking behaviour and this is at the core of the anxiety and conflict in the use of opioids 
for pain management. The way in which a patient presents has a huge influence on how much 
trust there is during the consultation and therefore on how likely the patient and GP are to 
agree on a management plan. Some of the physician’s demonstrated much empathy for a 
patient in pain, but this empathy when coupled with a lack of options for managing CNMP 
means that inappropriate prescriptions are more often given. This is not to suggest that the 
pain shouldn’t be treated but that the limited options for CNMP available in most primary 
care settings leave physicians with few options. 
“You have to show a patient you you’re empathetic to him. There is a pain. Pain is real” 24 
However, by displaying empathy, trust is developed and it may perhaps be easier to reach 
treatment agreements when such avenues of therapy are appropriate and available. 
“There are people who have expressed an interest to me in not wanting to be on the medication 
any more. Some have admitted that they’re probably at some level of dependence or addiction 
and we have had open discussions about not wanting to need this medication anymore.’’ 26 
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System Level Factors 
This global theme describes the context and influences on the GP, patient and clinic. Whilst 
these variables change over time, they do not change in the duration of the consult itself and 
are therefore the static parameters in which the consultation occurs. Some of the basic 
themes within this were universal, that is they applied to all countries and types of practice 
setting, such as the GP identified need for education and training on opioid prescribing. Some 
were specific to certain models of healthcare, for example, in the USA only certain patients 
who had the correct type of insurance could reliably attend a pain clinic, which made patients 
without such insurance more problematic for GPs to manage as there was no external 
support. 
Across all countries, GPs worried that their prescribing practices were based on an 
unsystematic conglomeration of their previous experiences without any external guidelines 
on which to base their decisions.  
‘I suppose, the way I behave now prescribing for everything is a sort of rather woolly, nebulous 
product of everything I’ve done, particular experiences of dealing with pain.’ 21 
Some GP’s had specialist training in pain management as part of their initial training, but 
many felt like they were inadequately prepared and questioned the wisdom of leaving 
generalist primary care specialists to negotiate such a complex and potentially risky 
prescription management. 
‘‘It’s a mistake promoting doctors like me to [treat pain and addiction]. It would be a societal 
mistake to have addiction and pain medicine be managed without other support services... Most 
of us in primary care end up [doing it] by default. But that’s not good. That’s not something to 
be promoted.’’ 26 
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Another reason for the perceived inadequate preparation of GP’s for opioid prescription 
management is the scarcity of time and resources as the health systems of the USA and the 
UK become ever more stretched. A lack of training was identified across all settings, with 
many of the GP’s feeling that they had training needs in opioid and pain prescription 
management. 
“I think it’s [anxiety about what to prescribe] just due to lack of experience with using opioids 
for non-malignant pain... and because I haven’t really done a lot of palliative care either.” 27 
A lack of time to properly assess a patient and their pain needs were identified by GPs. 
“The biggest problem in the whole thing is lack of time. Typically, these are complex people with 
multiple problems, and you really could spend the whole appointment, more than 1 whole 
appointment, just talking about this [opioid agreement]… and you need to really sit down and 
go through a person’s record, and really try to make a more rational decision. I take it very 
seriously. It’s serious business. What if you do create an opiate problem for somebody? Because 
you’re not being careful enough about it?” 28 
Further, a lack of specialist and joined-up support for both addiction and pain management 
was identified as a failure of the systems, again in all settings. 
‘‘There is a really big access issue with the pain clinics right now…So, while I can refer them, 
their likelihood of getting an appointment, even with strong advocacy from me, is very low.” 26 
Many of the discussions about individual prescriptions also opened out to consideration of 
the wider issues in prescription opioid dependence and societal harm. Opioid prescriptions 
Page 14 of 28 
are subject to specific legislation, in most countries strong opioids are a controlled substance, 
primarily due to their association with misuse. Due to these tight controls on their 
availability, opioids, particularly the more potent drugs, can have a high monetary value in 
illegal sale and usage.  
“We have a responsibility to be careful with prescribing these medications, so when we get 
burned, society gets burned, patients get burned.” 25 
Monitoring appears in all four global categories and is such a cross cutting theme as GPs 
attempt to improve their management of CNMP and to ameliorate harm at both the patient 
and societal levels. GPs used contracts, sometimes to support their management and other 
times because they felt it was expected of them. There was much ambiguity around the use 
of contracts and a recognition that, whilst they could be useful, they also had the potential to 
damage the fragile patient-GP trust relationship. 
“The contract I really use so that it formalizes our relationship.it makes it easier if you have to 
take it to the next step and make this referral [to substance use disorder treatment].”26  
Many GPs thought that this change to the relationship was not productive and felt that it ran 
counter to the trust-based nature of their roles.  
“I think [drug screening is] destructive to a basic patient-doctor relationship. You’re there to 
help them and they can tell you their deepest, darkest secrets, but yet you’re policing them.  28” 
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Figure 3: Theoretical framework: Risk, suspicion and disagreement axes interact to shape the opioid prescribing 
decisions. These are also influenced by system level factors which are seen to encompass these other variables. 
Theoretical Model 
Through synthesis of basic themes to organising themes then global themes, an overarching 
theoretical model was developed (Figure 3). The model proposes that when faced with a 
decision to prescribe an opioid for a patient with CNMP, the GP, operates within this 
framework. The decision to prescribe is informed by the perceived or actual risks associated 
with prescribing an opioid for the patient, both physical and psychological, the risk axis (Y-
axis). This is balanced with the credibility of the pain complaint combined with the likelihood 
of developing aberrant drug behaviours, the suspicion axis (X-axis). At the centre of the 
decision-making process therefore is ingrained the GPs understanding of the physical, 
psychological and moral qualities of the patient, the credibility of their pain condition and 
potential for opioid misuse offset against the therapeutic appropriateness of the 
prescription. This is further balanced with the expectations of both parties in the 
consultation, the GP and the patient, the disagreement axis (Z-axis). If both parties agree 
about the desired outcome of the consultation, the issuing of an opioid prescription, is a fait 
accompli in that consultation. The healthcare system and legislative requirements relating 
to opioid prescriptions provide an inflexible environment in which the consultation takes 
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place, the system level factors. System level factors will not only differ for GPs internationally 
but on a regional and practice level basis. 
Discussion 
This study has reviewed the factors affecting the prescribing of opioids for CNMP by GPs in 
primary care. By integrating the findings of the qualitative literature and deriving a 
theoretical model, we hope to progress the discussion on this subject, from one which seeks 
to map factors related to opioid prescribing to one which seeks to provide practical solutions. 
As GPs are responsible for the burden of care, it is imperative that the dynamics of opioid 
prescribing specific to primary care are mapped in order to identify practice changes that 
are of direct relevance to GPs.  
The theoretical model that has been derived from the metasynthesis proposes that 
the factors underpinning the decision to prescribe are not weighted against each other in a 
risk/benefit equation as previously hypothesised in the literature. 29 Rather, it is proposed, 
that factors, in this case modelled as global themes, interact to affect the likelihood of a safe 
and effective prescribing outcome. For example, a young healthy patient with no co-
morbidities presents less risk than a multimorbid older patient. However, the younger 
patient may trigger concern for the GP if actively requesting a prescription for an opioid 
particularly in the absence of a defined aetiology. Therefore, the younger patient, while low 
on the risk axis will be higher on the suspicion axis. The likelihood of being prescribed an 
opioid will be further diminished if the patient and GP are unable to reach a shared 
understanding of the analgesic management plan for the patient.  
Opioids, although a highly effective family of analgesics, have a unique set of 
considerations that inform their use, the legal constraints surrounding their prescription and 
supply due to their potential for abuse and misuse, the side-effects of these medications 
together with their ill-defined benefits when used in the long-term. 30 These issues attach an 
element of stewardship to the prescribing of these agents, shifting the task to the more 
complex end of the prescribing spectrum. The public health and societal risks guiding the 
prescribing of opioids are akin to antibiotic stewardship; we propose that the policy 
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recommendations and practice guidance should also follow this model. However, at present, 
while we seek to manage antibiotic resistance on a public health level, the very real issues of 
mortality and morbidity with endemic opioid misuse is usually discussed as it pertains to an 
individual’s behaviour. In practice, this moral construct obfuscates the real core of the 
current opioid crisis, which is that of a very small number of widely available options in 
CNMP management and adequate pain control. The morality which is embedded within 
discussion of opiate use, but rarely acknowledged, also leaves little room for discussion of 
the non-pathophysiological dimensions of pain and the complex relationship between 
mental health and CNMP. 
A more objective and holistic view of patients with CNMP, especially that pain which 
does not have an identified aetiology, would perhaps lead to more psychological and 
physiotherapeutic interventions. These types of interventions are currently endorsed by the 
literature and within guidelines and are undoubtedly are of benefit to patients in the 
management of their pain condition. 30-32 However, at present access to these treatment 
pathways can be difficult for patients with CNMP. 33 Integrating psychological interventions 
into GP consultations is one strategy for overcoming the challenge relating to the limited 
access to such services. 32 For such interventions to be incorporated into any patient-
physician encounter, it is obviously essential that the patient’s pain experience is believed 
and accepted by the GP in the first place. Disbelief is often cited within the literature as a 
significant barrier for patients in accessing the supports they require. 34 
There is no doubt from the literature that pain control is a life changing intervention 
for many patients, but the risk benefit analysis of using opioids to this end is not often done 
in an objective way because of the attendant moral concerns around this class of drugs. 
Further, issues of health inequality are also often obscured by the morally loaded discussions 
around the opioid crisis. Patients who are of low socioeconomic position are at once more 
likely to experience untreated physical injuries and illnesses, more likely to have mental 
illnesses which contribute to or cause presentations of CNMP and are less likely to be 
managed in specialist facilities. 35 Thus, the burden of mortality is skewed towards the most 
vulnerable, towards those most likely to have pain and to be poorly managed within that 
pain. This fact needs to be part of the discussion too, as it is in and of itself an issue of morality 
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and without a consideration of this in planning novel strategies for stewardship, we will not 
target the people most in need. 
Increasingly, recommendations within the literature is for GPs to not prescribe any 
opioids except for palliative care. 30, 36 Such a change in prescribing strategies is a significant 
shift from current practice and perhaps oversimplifies the solution to the opioid epidemic 
and, as above, will further exacerbate the inequalities in pain management. Furthermore, 
this advice is not helpful for those GPs caring for patients already established on an opioid 
regimen with opioid tapering a resource intensive and challenging process. Such a stance is 
also challenging in the context of a healthcare system with limited access to specialised care 
and where the cost of non-pharmacological interventions is not subsidised by the healthcare 
system or cannot be met by the individual alone. 
Strengths and Limitations 
The thematic review was conducted systematically and methodically, with each stage of the 
research being validated by at least two authors however, it is possible that other 
interpretations may be derived from the papers included in the review. A systematic 
approach was taken to identify papers and the search was conducted by an experienced 
librarian. However, only papers that were published in peer-reviewed journals were 
identified as the search did not extend to grey literature. Methodologically the papers were 
similar, most utilised unstructured or semi-structured but in-depth interviews with GP’s 
within a standard non-theory based qualitative approach.  
Conclusion 
The prescribing of opioids for CNMP by GPs is influenced by factors relating to the specific 
patient, the consultation, experiences and perceptions of the prescriber as well as the 
healthcare system in which the GP operates. Rather than a relatively linear risk-benefit 
relationship, there is a complex interaction within the consultation between these various 
factors which affect the likelihood of a prescription being issued. The implicit morality 
judgment that is associated with the use of opioids is a key factor that is perhaps unique to 
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this class of drugs. Current policy recommendations directed at GPs oversimplify the 
complex process underpinning the initiation or continuation of opioids in primary care, it is 
therefore unsurprising that increasing trends in opioid prescriptions have remained 
stubbornly consistent. Further research and development of strategies based on overarching 
models of stewardship and specific tools for consultation need urgently to be developed. 
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Table 1: Characteristics of included studies 
Study Geographical 
Location 
Methods Participants Data Collection Aim Key Themes CASP score 
(max 10) 
Barry et al., 2010 USA Grounded 
theory 
using 
constant 
comparativ
e method 
for 
systematic 
inductive 
analysis 
23 office based 
physicians 
(13 women, 10 
men) 
Semi-structured 
interviews 
Identify barriers and facilitators to 
opioid treatment of chronic non 
cancer pain patients by office 
based medical providers 
Three key themes which were further 
subdivided into subthemes: 
Physician factors 
Patient factors 
Logistical factors 
8 
Bendtsen et al., 
1999 
Sweden Critical 
incident 
technique 
114 physicians 
(general 
practitioners and 
general practice 
registrars) 
Semi-qualitative: 
questionnaire 
Explore the qualities of dilemmas 
and considerations among 
physicians prior to deciding 
whether or not to prescribe opioid 
analgesics to patients in a primary 
care healthcare setting 
Concern about abuse and addiction 
with no proper indication for the drug 
Indication for the drug – acute or 
chronic pain 
8 
Bergman et al., 
2013 
USA Inductive 
thematic 
analysis 
14 Primary care 
practitioners 
26 patients with 
chronic pain 
One-time in 
depth interviews 
Develop a better understanding  of 
the respective experiences, 
perceptions and challenges that 
patients with chronic pain and 
PCPs face communicating with 
each other about pain management 
Role of discussing pain versus other 
primary care concerns 
Acknowledgement of pain and the 
search for objective evidence 
Recognition of patient individuality 
and consideration of relationships 
9 
Esquibel and 
Borkan, 2014 
USA Immersion/
crystallisati
on process 
generate a 
16 physicians Patient-physician 
dyads 
(interviews) 
To explore the ways in which 
opioids medication influence the 
doctor-patient relationship 
Pain considered as a biopsychosocial 
model 
Challenges to legitimise and treat 
non-objective pain 
10 
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thematic 
codebook 
Chronic opioid therapy is not the 
preferred pain management modality 
Feeling inadequate as a care provider 
in treating pain 
Pain relied many not be a top health 
priority 
Gooberman-Hill 
et al., 2011 
UK Thematic 
analysis 
27 GPs 
(13 men, 14 
women) 
Semi-structured 
interviews 
To explore GPs’ opinions about 
opioids and decision-making 
processes when prescribing 
‘strong’ opioids for chronic joint 
pain 
Are opioids the best option 
Managing adverse effects and 
assessing vulnerable patients 
Views about opioid addiction, 
withdrawal and misuse 
Importance of previous experience 
10 
Harle et al., 2015 USA Open 
coding 
thematic 
analysis 
15 family medicine 
and general 
medicine 
physicians (7 men, 
8 women) 
In-depth 
interviews 
To understand how primary care 
physicians perceive their decisions 
to prescribe opioids in the context 
of chronic noncancer pain 
management 
Physicians’ information needs and use 
- Importance of objective and 
consistent information 
- Importance of identifying 
‘red flags’ related risks to 
prescribing opioids 
- Importance of information 
about physical function and 
outcome goals 
- Importance of tacit 
knowledge and trust in 
patients 
Other decision making challenges 
related to opioids 
- Weighing potential 
therapeutic benefits against 
opioid risks 
- Time and resource 
constraints 
- The role of primary care 
specialties in managing pain 
10 
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Krebs et al., 2014 USA Qualitative 
immersion/
crystallisati
on 
approach 
14 primary care 
physicians 
(recruited from 5 
primary care 
clinics) 
Semi-structured 
interviews 
Understand physicians’ and 
patients’ perspectives on 
recommended opioid management 
practices and to identify potential 
barriers to and facilitators of 
guideline-concordant opioid 
management in primary care 
Three barriers to use of 
recommended opioid management 
practices: 
Inadequate time and resources for 
opioid management 
Relying on general impressions of risk 
for opioid use 
Viewing opioid monitoring as a law 
enforcement activity 
10 
Matthias et al., 
2010 
USA Thematic 
analysis 
20 (10 men, 10 
women from 5 
outpatient primary 
care clinics) 
Semi-structured 
interviews 
To elicit provider’s perspectives on 
their experiences in caring for 
patients with chronic pain 
Providers emphasised the importance 
of the patient-provider relationship 
asserting that productive 
relationships with patients are 
essential for good pain care 
Detailed difficulties they encounter 
when caring for patients with chronic 
pain including feeling pressurised to 
treat with opioids 
10 
Matthias et al., 
2013 
USA Emergent 
thematic 
analysis 
5 (3 female, 2 
male)(veteran 
affairs primary 
medical centre) 
Recording of 
consultations 
with patients 
Understand how physicians and 
patients with chronic 
musculoskeletal pain 
communicated about issues 
related to opioids 
Uncertainties about opioid treatment 
for chronic pain, particularly 
addiction and misuse 
10 
McCrorie et al., 
2015 
UK Grounded 
theory 
approach 
15 GPs (11 women, 
4 men) 
Focus groups Understand the processes which 
bring about and perpetuate long-
term prescribing of opioids for 
chronic, non-cancer pain 
Organisation of UK general practice 
Available therapeutic options 
Expertise in managing chronic pain 
10 
Seamark et al., 
2013 
UK Thematic 
analysis 
17 (interviews) 
5 (focus group) 
Semi-structured 
interviews 
Focus group 
To describe the factors influencing 
GPs’ prescribing of strong opioid 
drugs for chronic non-cancer pain 
Chronic non-cancer pain is seen as 
different from cancer pain 
Difficulties in assessing pain 
Effect of experience and events 
9 
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Spitz et al., 2011 USA Directed 
content 
analysis 
23 physicians Six focus groups Describe primary care providers’ 
experiences and attitudes towards, 
as well as perceived barrier and 
facilitators to prescribing opioids 
as a treatment for chronic pain 
among older adults 
Fear of causing harm 
Pain subjectivity 
Concerns about regulatory and/or 
legal sanctions 
Perceived patient- level barriers to 
opioid use 
Greater comfort in using opioids in 
palliative care 
Frustration treating pain in primary 
care 
9 
Starrels et al., 
2014 
USA Grounded 
theory 
approach 
28 primary care 
providers (18 
women, 10 men) 
Semi-structured 
telephone 
interviews 
To determine primary care 
providers’ experiences, beliefs and 
attitudes about using opioid 
treatment agreements for patients 
with chronic pain 
Perceived effect of OTA use on the 
therapeutic alliance 
Beliefs about the utility of OTAs for 
patient or providers 
Perception of patients’ risk for opioid 
misuse 
9 
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Table 2 Basic codes, organising and global themes 
Suspicion Axis Risk Axis Disagreement Axis System Level Factors 
Trust and mistrust 
I’m not abusing anything – 
the fine line between pain 
control and abuse 
Medical or psychiatric 
comorbidity 
Undiagnosed focus or cause 
Disruptive influence of 
substance use disorder 
Psychological or non-pain 
reasons to take opioids 
Health system gaming – 
benefits insurance and 
selling prescriptions 
If you can’t see the dilemma 
in this situation 
Patient asking for opioids 
and losing physicians 
respect 
Demographics, stigma and 
stereotyping 
Aberrant medication use 
Importance of aetiology 
Objective pain assessment 
Appropriate indication – 
arising from objective 
evidence 
Medical or psychiatric 
comorbidity 
Undiagnosed focus or cause 
assumption of abuse 
Monitoring 
Assessment 
Patient frustration with 
inadequate pain 
management 
Drug testing and contracts 
Monitoring 
Physicians concerns for side-
effects and addiction 
Follow up and review 
Physical and psychological 
harm 
Physicians concern for side 
effects and addiction 
If you can’t see a dilemma in 
this situation 
Aberrant medication use 
Medical or psychiatric 
comorbidity 
The morality of addiction 
If you can’t see the dilemma 
in this situation 
I’m not abusing anything – 
the fine line between pain 
control and abuse 
Health systems gaming – 
benefits, insurance and 
selling prescriptions 
Patient asking for opioids 
and losing physician respect 
Drug testing and contracts 
Monitoring 
Assessment 
Patient frustration with 
inadequate pain 
management 
Drug testing and contracts 
Monitoring 
Physicians concern for side-
effects and addiction 
Follow up and review 
Adverse effects 
Disruptive influence of 
substance use disorder 
Aberrant medication use 
Consult variables 
Managing pain and opioid 
conversations 
Physician guilt and 
maintaining trust 
Physician frustration with 
patient 
Patient influences 
Prescribing practices 
Empathy 
Consultation 
Assessment 
Patient frustration with 
inadequate pain 
management 
Adverse effects 
Physician concern for side-
effects and/or addiction 
Patient asking for opioids 
and losing patient respect 
Demographics, stigma and 
stereotyping 
Disruptive influence of 
Substance Use Disorder 
Knowledge and training 
Lack of clinical guidelines – 
vague 
Service limitations, time and 
resources 
Inadequate pain 
management 
Patient frustration with 
inadequate pain 
management 
I’m not abusing or anything 
– the fine line between pain
control and abuse 
Systems 
Lack of clinical guidelines – 
vague 
Service limitations, time and 
resources 
Cost and expense 
Law enforcement and 
rationing 
Lack of training 
Knowledge and training 
Health system gaming – 
benefits, insurance and 
selling prescriptions 
If you can’t see the dilemma 
in this situation 
Patient asking for opioids 
and losing physician respect 
Disruptive influence of 
substance use disorder 
Monitoring 
Drug testing and contracts 
Disruptive influence of 
substance use disorder 
Aberrant medication use 
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Adverse effects 
Disruptive influence of 
substance use disorder 
Aberrant medication use 
